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DaPoint-of-care technologies (POC or POCT) are enabling innovative cardiovascular diagnostics that promise to improve
patient care across diverse clinical settings. The National Heart, Lung, and Blood Institute convened a working group to
discuss POCT in cardiovascular medicine. The multidisciplinary working group, which included clinicians, scientists, engi-
neers, device manufacturers, regulatory ofﬁcials, and program staff, reviewed the state of the POCT ﬁeld; discussed op-
portunities for POCT to improve cardiovascular care, realize the promise of precision medicine, and advance the clinical
research enterprise; and identiﬁed barriers facing translation and integration of POCT with existing clinical systems. A POCT
development roadmap emerged to guide multidisciplinary teams of biomarker scientists, technologists, health care pro-
viders, and clinical trialists as they: 1) formulate needs assessments; 2) deﬁne device design speciﬁcations; 3) develop
component technologies and integrated systems; 4) perform iterative pilot testing; and 5) conduct rigorous prospective
clinical testing to ensure that POCT solutions have substantial effects on cardiovascular care. (J Am Coll Cardiol Basic Trans
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74T he prevention and management ofcardiovascular (CV) disease increas-ingly demands effective diagnostic
testing. Consensus deﬁnes a diagnostic as a
method and an associated device that per-
forms a physical measurement from a patient
or associated biological sample and produces
a quantitative or descriptive output, known
as a biomarker. The deﬁnition of a
biomarker, in turn, encompasses “a charac-
teristic that is objectively measured and
evaluated as an indicator of normal biolog-ical processes, pathogenic processes, or pharmaco-
logic responses to a therapeutic intervention” (1).
Diagnostics, because of their strategic position at
the intersection between patients and their clinically
actionable data, directly affect the patient experience
and the quality of care that individuals receive
(Figure 1). They also furnish valuable tools for clinical
investigation. Diagnostics enable providers to
improve upon “one-size-ﬁts-all” treatment strategies
and instead provide personalized care on the basis of
factors such as genetic makeup, comorbidities, real-
time serologic assessments, and responses to therapy.
Historically, during the days of “house calls,” diag-
nostic testing relied primarily on physical examination
and bedside analysis of urine (2). As methods for
biochemical and cellular bioﬂuid analysis advanced,
the portfolio of available tests expanded and central
laboratories emerged to standardize sample acquisi-
tion and measurement quality while offering econo-
mies of scale (3). Today, technology is expanding the
number of diagnostic tests that can reach beyond the
walls of centralized laboratories and back to the point
of care (POC) for use across a broad range of clinical
settings. Yet, despite the intuitive appeal of minia-
turization and immediate test resulting, point-of-care
technologies (POCTs) face important practical ques-
tions about their integration into clinical workﬂows,
objective measurement of clinical beneﬁt, standards
necessary to ensure quality despite decentralization,
and what reimbursement models will engender
mutual enthusiasm by payers and providers.
POCTs promise to provide high-quality biomarker
measurements optimized for the special constraintsstitute; has been a speaker for Daiichi Sankyo and Merck; and h
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outpatient clinics, clinical research centers, homes,
rural areas, and the developing world (Figure 2). In
acute care settings such as the operating room (OR),
cardiac catheterization suite, intensive care unit
(ICU), or emergency room (ER), physicians seek real-
time feedback to optimize care and tailor therapies
to the dynamic circumstances they confront. In
outpatient clinics, providers look for opportunities to
replace reactive medicine with prevention, and to
implement “precision medicine,” a national initiative
that includes mobile and personal technologies as key
components (4). In the home, care teams seek mini-
mally invasive devices that seamlessly integrate
health monitoring into daily living. The hope is that
longitudinal measurements of home health will sup-
plement episodic clinic visits and transform outpa-
tient care into a data-driven practice. Independent of
their health care providers, the public is adopting
diverse POC-like self-tracking devices such as sleep
monitors, Wi-Fi–connected scales, blood pressure
cuffs, ﬁnger-stick blood tests, and wearable wrist-
bands and watches linked to cloud storage, analytics,
and opportunities for sharing. The degree to which
such technologies will improve health care delivery
and clinical outcomes remains hotly debated. Ulti-
mately, only rigorous testing will determine their
actual clinical utility.
In clinical research, POCTs can expand quantitative
data collection to broader populations. By fostering
inclusion of under-represented groups in rural areas
and the developing world often beyond the reach of
traditional clinical trials, POCTs promise to improve
the generalizability of study results (5–7).
The National Heart, Lung, and Blood Institute
(NHLBI) convened a working group (WG) to examine
the translation of CV POCT to precision medicine and
clinical research (8). The meeting aimed to provide
guidance to the NHLBI regarding the development,
evaluation, and dissemination of high-impact POCT
in research and treatment. This report summarizes
and expands upon the WG discussions by: 1)
describing examples of how POCT can address some
of the most commonly faced problems in CV disease
management; 2) identifying barriers and challengesolds a patent in personalized antiplatelet therapy in
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FIGURE 1 Diagnostics
Diagnostics obtain measurements from a patient or associated
biological sample and produce quantitative or descriptive
outputs known as biomarkers, which enable clinical care, patient
communication, and clinical research.
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75to clinical translation; 3) calling for rigorous clinical
testing and validation before integrating new POCTs
into routine clinical care; and 4) outlining a POCT
development roadmap that articulates speciﬁc rec-
ommendations to guide NHLBI research priorities.
IPOC EXAMPLES, CHALLENGES,
AND OPPORTUNITIES
POCT IN ACUTE CARE SETTINGS. Practitioners in
acute care settings such as the ER, OR, ICU, hemodi-
alysis unit, or cardiac catheterization suite face highly
dynamic situations. Real-time POCT promise to
improve patient care in these environments by sup-
plying data rapidly to support decision-making, as
illustrated in the following examples.
Example 1: rapid evaluation of ER patients with chest
pain—“rule out myocardial infarction”. In ambulances
and ERs, POCT can improve the efﬁciency of care by
enabling rapid assessment and triage of patients
with chest discomfort. Cardiac troponin (cTn), a
highly sensitive and speciﬁc biomarker of myocardialFIGURE 2 Point-of-Care Technologies
Point-of-care technologies (POCTs) are positioned to address the
special constraints of diverse clinical settings including acute
care, outpatient clinics, clinical research centers, homes, rural
areas, and the developing world.injury, guides triage and management of patients
presenting with symptoms suggestive of acute coro-
nary syndrome (9). ERs already use commercial POC
cTn assays, but parallel efforts are exploring whether
central laboratory cTn assays can perform serial
measurements at progressively shorter intervals to
discriminate cardiac from noncardiac causes of chest
discomfort and enable rapid patient triage. Histori-
cally, stable serial measurements of cTn taken at 6- to
12-h intervals served to “rule out” cardiac injury
(10,11). More recently, high-sensitivity cTn assays,
available only in the central laboratory, permit
exclusion of clinically important myocardial injury
with high conﬁdence at initial sampling as well as
after only 2 serial measurements performed at 1- to 2-
h intervals (12–15). POC devices that can match this
performance without sending samples to a central
laboratory may become mainstream frontline CV di-
agnostics (Figure 3A).
Example 2: management of bleeding and clotting
risks. The quandary of balancing the risks of bleeding
and clotting concerns practitioners of many spe-
cialties. Clot formation involves complex interactions
among coagulation factors, platelets, and tissues
(16). Surprisingly, a limited number of coagulation
diagnostics guide routine outpatient and inpatient
management (17,18). Central laboratories typically
measure 2 key coagulation parameters: prothrombin
time and activated prothromboplastin time. Yet,
delays of w1 h limit the utility of central laboratory
measurements for acute care settings such as the
ICU or OR, where thrombotic risk can vary moment
to moment due to administration of anticoagulant
boluses and pharmacological reversal agents (19–21).
In these settings, activated clotting time (ACT), a
whole blood measurement that integrates intrinsic
and extrinsic coagulation with platelet function,
commonly serves to quantify thrombotic potential
(21). In the case of ACT measurements, procedural
technicians, within steps of patient and procedur-
alist, perform POC testing independent of the central
laboratory. This example illustrates the feasibility
of integrating real-time POC diagnostics into acute
clinical workﬂow (Figure 3B).
Platelet function complements coagulation in
regulating thrombotic risk. Yet, despite extensive
studies of platelet function assays in both central
laboratory and POC formats, questions remain
regarding their incremental beneﬁts. Measures of
platelet function do identify populations at higher
risk of thrombotic events, but the demonstration that
therapy guided by such assays improves outcomes
has proven elusive (22–24). This apparent paradox
underscores the need to subject any POC diagnostic,
FIGURE 3 Dynamic Biomarkers for POCT Measurement
(A) In the emergency room, high-sensitivity troponin assays resolve small differences in troponin levels to rule out clinically important
myocardial injury after serial measurements performed at increasingly short time intervals. (B) In the cardiac catheterization laboratory and the
cardiac surgery operative room, activated clotting time (ACT) measurements are used to follow the dynamics of patient coagulation.
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76no matter how plausible, to rigorous research to
evaluate its efﬁcacy and added value. Coagulation
and platelet function biomarkers exhibit variability
and context-dependence, adding complexity to their
clinical use (25,26). POC diagnostics offer the poten-
tial to capture these variations through more frequent
measurement, but whether doing so substantially and
cost-effectively improves outcomes will require
additional research (Figure 4).
Exploratory thrombosis assays aim to complement
existing assays of thrombotic risk. Examples include
clot relaxation (27) or thromboelastography (16),
which evaluate viscoelastic properties of clot forma-
tion. Although such assays were initially considered
to be too complex for routine clinical use, recent POC
adaptations of these measurements aim to improve
usability (18,28).
Example 3: future acute care POC assays. Reliable
detection of thrombosis presents a diagnostic chal-
lenge. Available POC devices can measure thrombosis
serum biomarkers such as D-dimer, which notori-
ously lacks speciﬁcity. Often, acute D-dimer eleva-
tion due to thrombosis cannot be distinguished from
chronic elevation related to comorbid conditions.
Instead, modern diagnosis of deep vein thromboses
and pulmonary emboli relies primarily on imaging
modalities such as ultrasound or contrast chest
computed tomography, respectively. Recently, exog-
enous “synthetic biomarkers” were engineered to
supplement endogenous biomarkers and enable
more ﬂexible remote monitoring of thrombosis. In
concept, an intravascular nanoparticle-conjugated
peptide, when cleaved by activated thrombin, liber-
ates a peptide fragment that undergoes renalclearance detectable in the urine centrally or by POC
platforms, such as novel paper-based microﬂuidic
assays (29–31) (Figure 5A). Similar synthetic biomarker
strategies are under development for a broad range
of analytes.
In principle, continuous biomarker monitoring
would provide the most complete picture of an in-
dividual’s physiological state. Historically, the ability
to measure continuously physicochemical bio-
markers such as blood pressure, pulse, electrocar-
diogram, respiration rate, and oxygen saturation
revolutionized critical care and substantially
improved the safety of general anesthesia. Contin-
uous vital sign measurements have become the
standard of care for periprocedural CV monitoring;
however, efforts to engineer continuous blood
biomarker measurement platforms that monitor
“biomolecular vital signs” presents more challenging
problems, whose solutions are only nascent (32). The
most notable clinically relevant analyte adapted for
continuous measurement is glucose. Glucose is
readily detected by diverse electrochemical-sensing
platforms coupled to an immobilized enzyme
(glucose oxidase); yet, the lack of broadly available
analyte-enzyme pairs limits the generalizability of
this approach. More recently, reversible afﬁnity sen-
sors have promised to expand the portfolio of ana-
lytes subject to continuous monitoring. For example,
a microﬂuidic device containing a sensing surface
functionalized with nucleic acid-based aptamers can
reversibly bind corresponding analytes. The ﬂuidic
device directs blood across the planar sensing surface
separated by a layer of buffer solution (Figure 5B)
such that only biomolecules below a critical
FIGURE 4 POCT for Antithrombotic Therapy
Many patients have indications for both anticoagulation (e.g.,
atrial ﬁbrillation, venous thromboembolism, mechanical heart
valve) and antiplatelet therapy (e.g., myocardial infarction or
percutaneous coronary intervention). There is limited clinical trial
data to guide the use of these agents in combination therapy.
New diagnostics could aid selection and titration of combination
regimens to personalize care by optimizing the risks of bleeding
and clotting.
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77molecular weight can diffuse across the buffer layer
and encounter the sensing surface. The reversible
binding of analytes to their corresponding immobi-
lized aptamer then generates an electrochemical
signal proportional to blood analyte concentration
(33). The ﬂexibility of such platforms is expanding as
the number of available analyte-aptamer pairs grows.
This example also illustrates the exciting potential
enabled by integrated microﬂuidic platforms, which
operate at ﬂow rates less than microliters per minute,
and can in theory enable continuous blood draws
over hours and days while keeping total blood
volumes below that of a single conventional blood
draw.
POCT IN AMBULATORY SETTINGS. In outpatient
clinics, the brevity of the patient visit rather than the
dynamics of the physiological state provide the
motivation for POC diagnostic testing. Patients
frequently have blood drawn for diagnostic testing
after a clinic visit. Unfortunately, the ad-hoc
follow-up discussions of testing results can lead to
undesirable breaks in patient-provider communica-
tion. A current movement calling for more diagnostic
testing in the clinic aims to resolve such in-
efﬁciencies. POC diagnostic platforms in develop-
ment aim to answer these challenges by enabling
measurement of existing biomarkers as well as
fundamentally new biomarkers that can enhance the
outpatient practitioner’s diagnostic toolkit.Example 1: miniaturization and mobilization of existing
laboratory diagnostics. The earliest examples of POC
diagnostics aimed to miniaturize and make portable
the measurement of established biomarkers such as
the complete blood count or basic metabolic panel.
Yet, clinical use of such POC diagnostics has not
kept pace with the number of commercially available
testing platforms. Instead, there is continued reli-
ance on central laboratories, which likely points
to challenges presented by new POCT, including
cost, uncertain reimbursement, requirements for
calibration with legacy central laboratories, stan-
dardization of testing procedures, veriﬁcation of
testing expertise, maintenance of the decentralized
testing equipment and procurement of disposables,
and establishment of good data management prac-
tices including security and privacy. Despite these
challenges, miniaturized and mobilized versions of
existing diagnostic tests, being the ﬁrst POCT
diagnostics to enter clinical CV care and research,
will likely serve as vehicles for addressing these
challenges.
Example 2 : persona l i zed CV care us ing nuc le i c
ac id assays . Whether nucleic acid-based assays
should be adapted to POC formats remains an area of
ongoing investigation. Deoxyribonucleic acid (DNA)–
based diagnostics have enjoyed success in oncology
because particular DNA mutations inform therapy
efﬁcacy. Similarly, in infectious disease, detection of
the DNA from an invading pathogen carries clear
diagnostic information. Cardiologists, however, have
used DNA diagnostics primarily for monogenic con-
ditions. One exception is the assessment of rejection
of transplanted hearts, where cell-free (cf) DNA se-
quences can selectively detect donor heart damage.
Indeed, circulating donor cfDNA levels correlate with
episodes of acute rejection as determined by inva-
sive endomyocardial biopsy (34,35). Detection of
donor cfDNA enabled prospective noninvasive diag-
nosis of acute rejection with sensitivity and speci-
ﬁcity comparable to the biopsy alone (35). A similar
cfDNA sequencing approach examined the evolving
pathogen landscape in heart transplant recipients
in response to changes in their immunosup-
pressant and antiviral regimens (36). Determining
the utility of POC genomic assays for CV transplant
rejection or infection assessment will require addi-
tional research.
RNA, in contrast to DNA, can change dynamically
during disease, making it an attractive biomarker for
next-generation CV diagnostics. The complex and
multifactorial nature of CV diseases has motivated
exploration of transcriptional proﬁling. One approach
uses a 23-gene expression assay platform on the basis
FIGURE 5 Next-Generation POCT Sensing Strategies
(A) Synthetic urinary biomarkers are being developed to augment endogenous biomarkers and enable noninvasive monitoring of intravascular
thrombosis. A peptide conjugated to a nanoparticle is cleaved in the presence of thrombin and liberates a peptide fragment that is cleared by
the kidney and can be detected in the urine. (B) Microﬂuidic continuous biomarker monitoring devices allow analytes to diffuse from blood to
an electrochemical sensing surface modiﬁed with aptamers that reversibly bind them enabling continuous monitoring.
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78of microﬂuidics and dehydrated primers, which
measures gene expression ﬁngerprints from circu-
lating cells (37,38) to provide negative predictive
power to limit the need for more elaborate CV testing.
The assay, which in its current instantiation is still
far from POC, requires shipment of samples to a
central facility. Nonetheless, this early example
demonstrates the feasibility of using gene expression
ﬁngerprinting as a discriminatory CV biomarker.
Example 3: next-generation integrated diagnostics
platforms. In addition to soluble proteins and cell-
based or cell-free nucleic acids, emerging biomarkers
such as rare circulating cells, mRNA, and exosomes,
and their contents hold diagnostic promise (39–42).
Platforms based on microtechnology and nanotech-
nology can capture rare analytes from crude patient
samples, fractionate specimens, and quantify bio-
markers using signal ampliﬁcation and integrated
detection schemes.
Microtechnology uses devices with dimensions on
the order of the thickness of a human hair. Built using
fabrication techniques originally developed for the
microelectronics industry and extended to micro-
electromechanical systems, these devices are ideally
suited for POC handling and analysis of small volumes
of complex biological ﬂuid specimens such as blood
or urine (43,44). Fabrication in transparent biocom-
patible polymers renders these devices compatible
with conventional optical detectors. Engineers have
developed increasingly powerful integrated ﬂuid
handling components that now enable dense arrays ofhighly efﬁcient pumps and valves to precisely control
movement of ﬂuids, solutes, and cells (45,46). This
powerful toolkit has enabled the design of diagnostic
devices that perform a variety of functions, including
particle and cell sorting, rare cell capture, and
massively parallel and sequential biochemical re-
actions (41). The design ﬂexibility enabled by micro-
technologies offers broad utility for the development
of POCT devices. Deﬁning clear diagnostic problems in
CV medicine that can harness the creativity of this
community holds great potential.
Nanoscale devices have a length scale 3 orders of
magnitude smaller than that of microfabricated de-
vices. Nanoparticles are key components of these
technologies. Among the many ways to detect nano-
particles, strategies on the basis of magnetic proper-
ties of the particles or surface plasmon resonance
represent particularly elegant examples (47–49).
Extension of the size scale of particles can allow
sensing by commercially available detectors such
as smartphones. For example, in an application
requiring counting of cell subsets, investigators
bathed biological samples in microbeads conjugated
to cell-speciﬁc antibodies and used the diffraction
pattern of cells decorated with antibody-conjugated
beads to identify and count the cell population of
interest using a custom dongle attached to a com-
mercially available smartphone (50). Several excel-
lent reviews describe these technologies in further
detail and describe examples of additional POC
applications (5).
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79POCT IN THE HOME. Patients spend <1% of their lives
interacting with the health care system in the tradi-
tional sense. They spend the remaining >99% in the
outside world, “at home.” Innovative technologies
such as the Internet of Things, wearable devices,
mobile communication devices, and social networks
promise to improve fundamentally our understand-
ing of human health and transform the home into the
next frontier of outpatient medicine.
Outpatient clinical visits frequently begin with
open-ended questions such as “have you been taking
care of yourself at home?” This question calls on pa-
tients to summarize months of post-prandial glucose
levels and blood pressure measurements, as well as
adherence to recommended exercise, diet, or pre-
scription medications. The availability of more
objective and quantitative data can paint a dynamic
and unbiased picture of home health across time.
Balancing the desire to inform but not overburden
providers with extraneous or unactionable informa-
tion will require thoughtful data synthesis and ana-
lytics to traverse efﬁciently the voluminous data.
Third-party disease management businesses may
serve as intermediates. Nevertheless, successful
navigation of the “big data” problem will transform
the home into an informative lens through which one
can observe patient health.
The following examples demonstrate the breadth
of home health monitoring devices currently avail-
able or in development. Together, these technologies
promise to create a more comprehensive picture of
patient health and behavior that can complement
patient self-reporting during in-person health care
visits.
Example 1: self-testing POC diagnostics. Blood glucose
testing remains one of the oldest and most widely
accepted POC applications. Yet, despite substantial
investment and widespread use, few sufﬁciently
powered studies have examined the clinical utility
and cost-effectiveness of glucose self-monitoring
(51,52). Meta-analyses estimate glycated hemoglobin
declines of 0.22% to 0.40% in patients using
blood glucose self-monitoring compared with control
subjects (52,53). Although these studies did not
directly evaluate the effect on clinical outcome,
this magnitude of reduction associates with a sig-
niﬁcantly reduced risk of microvascular complica-
tions in other clinical trials (54). Studies that involved
the inclusion of glucose self-monitoring as a com-
ponent of a structured therapeutic management
program, including education and follow-up, yielded
the greatest improvements in outcomes (55).
Monitoring of anticoagulation in warfarin-treated
individuals with POC international normalized ratiomeasurements furnishes another example of self-
testing. A meta-analysis of 11 randomized controlled
trials showed signiﬁcant reductions in the risk for
thromboembolic events (hazard ratio: 0.51; 95% con-
ﬁdence interval [CI]: 0.31 to 0.85), with no increase in
major hemorrhagic events or death (hazard ratios:
0.88; 95% CI: 0.74 to 1.06; and 0.82; 95% CI: 0.62 to
1.09, respectively) in patients who self-monitored
compared with patients who did not (56). In addi-
tion, the coupling of self-monitoring with self-
management and dosing was associated with greater
risk reductions. Thus, although self-monitoring of
the international normalized ratio may not beneﬁt
all patients, wider access and availability of testing
in the home can strengthen the effectiveness of care.
Example 2: connected diagnostics—wearables, smart
phones, and the “Internet of Things.” Wearables. The
ability to position sensors onto a patient and into the
clothing they wear has powerful potential to trans-
form our understanding of CV health and disease.
These categories of POC devices, sometimes termed
“wearables,” a subset of the “internet of things,” the
“Internet of Things,” have captured the imagination
of physicians and patients alike. The earliest versions
of internet-connected home health devices simply
adapted conventional diagnostics previously used in
the clinic or hospital, such as blood pressure cuffs,
heart rate monitors, scales, pedometers, oximeters,
and positive pressure ventilation controllers.
Telehealth programs and chronic disease
management practices developed systems to
monitor data from these sensors, provide feedback
regarding results to providers and/or patients, and
encourage compliance using reminders. More
recently, wearable technologies such as wristbands
and watches equipped with integrated microscale
accelerometers have enabled activity monitoring,
performance feedback, and the ability to annotate
data with subjective measures of health for sharing
with friends, family, health care providers, or the
world.
High-performance electronic circuits play an
essential role in home health devices, but rigid circuit
boards and wires present a barrier to miniaturization
and integration into ambulatory-sensing solutions.
The recent development of a ﬂexible electronics
platform permits the fabrication of high-functioning
electronic devices into thin ﬂexible tattoo-like trans-
parent ﬁlms that adhere to the skin (57,58,63,64).
The durability of initial prototypes underwent
testing in challenging locations such as the elbow
without signal degradation over days despite
repeated extension and ﬂexion. Transmission of
the electrocardiogram and electroencephalogram
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80conﬁrmed the functional utility of the device. Opti-
mization of such technologies should permit con-
tinuous remote measurements in outpatients.
Monitoring of atrial ﬁbrillation could beneﬁt from
such advances. The burden of atrial ﬁbrillation and
the frequency of atrial ﬁbrillation paroxysms likely
correlate with stroke risk (59,60). The emergence of
minimally invasive heart rate and rhythm-monitoring
devices on the basis of ﬂexible electronics and other
technologies offers a unique opportunity to docu-
ment longitudinally patient rhythms in relation to
other life events (61). Such information would
enhance our understanding of triggers associated
with arrhythmia onset and termination and aid pa-
tient management.
Internet of Things. A movement termed the “Internet
of Things” aims to convert the home into a densely
interconnected environment with embedded sensors
in everyday objects that can monitor, communicate,
and connect the environments in which we live. As an
example of this technology, bedroom-embedded
sleep monitors aim to optimize rest and detect
sleep-disturbed breathing. The embedded sensing
concept, although still in its earliest stages, has
excited CV care providers with the possibility
of devices that will monitor high-risk patients,
identify early warning signs of decline, and prompt
early intervention that may avoid more severe
decompensation.
Management of heart failure is particularly poised
to beneﬁt from emerging home health technologies
(62). Heart failure affects more than 5 million
U.S. patients, triggers >1 million hospitalizations
annually, and associates with remarkably highFIGURE 6 Management of Patients With Heart Failure Will Beneﬁt
This patient population is beneﬁting from new point-of-care technologi
decompensation (e.g., symptoms, weight, and ventricular ﬁlling pressur
hospitalizations. BBQ ¼ barbecue, a high-salt meal.rehospitalization rates (w25% at 30 days and w50%
by 6 months) (63). Because weight gain often pre-
cedes hospitalization by days to weeks, some guide-
lines recommend that patients weigh themselves
daily at home. Unfortunately, adherence to this
recommendation remains poor; in a recent large-scale
clinical trial, compliance with telemonitoring fell
from 90% to 55% by 6 months despite implementa-
tion of an aggressive reminder system (64). This
deﬁciency challenges disease management teams and
practitioners caring for patients at home. Hence, a
need exists to develop devices that monitor activity
and/or weight without proactive patient participa-
tion. Doing so should improve the regularity of home
testing and may avert unnecessary hospitalizations
through early detection of volume overload
(Figure 6).
Medication compliance also received early atten-
tion. Adherence to recommended pharmacological
therapy remains an important but often unappreci-
ated challenge of outpatient CV care. This challenge
spurred the development of Wi-Fi–connected pill
bottle caps and internet-connected sealable blister
packs, inhalers, or injectables to provide new
windows into patient medication compliance. This
capability enables study of whether incentivization
strategies and gamiﬁcation can improve adherence to
daily medications such as statins. Although recording
patient medication access times does not directly
reveal ingestion, these data nevertheless provide
previously unobtainable information about patient
medication habits at home. To measure more directly
medication adherence, developers have created a
microchip sensor-enabled pill with Food and DrugTremendously From POCT in the Home
es (POCTs) that longitudinally monitor biomarkers of heart failure
es) to guide adjustments in diuretic dosing and avoid unnecessary
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81Administration (FDA) clearance that communicates
with an adhesive patch worn on the torso that records
when the pill is ingested (65). Early studies using this
technology reportedly suggest that patients with
greater irregularity in the timing of their morning
medication were more likely to miss doses alto-
gether and had lower medication adherence rates
across time. This result suggested that interventions,
such as incorporating therapy into a different facet
of a daily routine, might improve compliance.
Combining integrated sensing technologies such as
these with behavioral studies is a fertile area for
future research.
Smartphones. Smartphones serve as powerful plat-
forms for software and hardware developers
to collect, store, manage, and communicate health
sensor data. In the CV space, a smartphone case
with integrated contact electrodes allows a user
to measure continuously an electrocardiographic
rhythm strip simply by holding the case with 2 hands.
Combined with rhythm detection software and the
ability to save and share tracings, this technology has
the potential to expand greatly patient self-recording
of single-lead heart rhythms. For diabetic individuals,
an electrochemical blood glucose meter that attaches
to commercial smartphones as a dongle can measure,
store, and analyze glycemic control. Similarly, full
laboratory-quality immunoassays have also been
miniaturized and adapted to a custom dongle
attached to a commercial smartphone (66).
Smartphones have generated tremendous excite-
ment for use in clinical research. Apple’s Research-
Kit (Apple, Cupertino, California), which was
downloaded with great enthusiasm upon its initial
release, allows users to participate in clinical
research via their smartphones and iPads. Applica-
tions focusing on CV disease (MyHeart Counts) and
diabetes management (GlucoSuccess) were among
the initial offerings and feature the ability to
monitor activity, self-record a 6-min walk test, and
record dietary habits and medication adherence.
Google X, Duke, and Stanford also recently
announced an ambitious project, the Baseline Study,
which aims to understand what keeps people
healthy and what determines disease trajectories. As
the pilot phase of the study gives way to larger co-
horts, reports suggest that the study will collect
genomic information and employ more complex
human phenotyping from the “Study Kit” applica-
tion, associated devices, and even wearables such as
the much anticipated “smart” contact lenses. These
innovations extend the POC concept to everyday life
and provide enormous potential for mining “bigdata” for health purposes at a population level, but
also enabling precision medicine or personalized
management for the individual.
Example 3: invasive outpatient health monitors.
Implantable monitors are inherently invasive and,
therefore, require careful consideration of safety
before use. Once placed, however, this class of
monitoring devices makes several potentially
powerful biomarkers available to providers longitu-
dinally across time. For example, implantable rhythm
recorders as well as conventional pacemakers and
implantable cardiac-deﬁbrillators can detect rare but
concerning paroxysmal ventricular arrhythmias as
well as exhaustively proﬁle the timing and burden of
chronic arrhythmias such as atrial ﬁbrillation. An
ambulatory intrathoracic impedance monitor and
associated algorithm attempt to identify thresholds
and temporal signatures of impedance changes that
predict worsening heart failure (67–69). Another de-
vice still in development directly measures left
ventricle ﬁlling pressures in the left atrial appendage,
but requires transseptal puncture for device place-
ment. The data, which are transmitted to a hand-held
patient advisory tool, can then guide medication
dosing changes according to an algorithm. Taking a
different approach, a new FDA-approved implantable
pulmonary artery pressure monitor can be placed
during a right heart catheterization and does not
require a transseptal puncture. In the COMPASS-HF
(Chronicle Offers Management to Patients With
Advanced Signs and Symptoms of Heart Failure) trial
that evaluated this technology, increases in PA pres-
sure were reportedly more sensitive and speciﬁc, and
they anticipated weight increase associated with
decompensation (70,71). Support for device approval
largely stems from the CHAMPION (CardioMEMS
Heart Sensor Allows Monitoring of Pressure to
Improve Outcomes in NYHA Class III Heart Failure
Patients) trial, which demonstrated that in New York
Heart Association functional class III heart failure
patients hospitalized in the past 12 months, manage-
ment guided by the pulmonary artery pressure
monitor signiﬁcantly reduced heart failure admis-
sions (72).
PRACTICAL ASPECTS OF
POCT IMPLEMENTATION
CLINICAL TESTING AND VALIDATION OF POCT.
POCT development must balance the enthusiasm for
promising new diagnostic platforms with the need for
rigorous validation studies. Adoption of a new device
should depend on demonstrated performance
compared with reference standards of care to ensure
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82that it provides similar or improved clinical utility.
Even if POC diagnostics cannot demonstrably alter
hard outcomes such as survival, they may provide
added value by limiting lengths of stay, reducing
readmissions, avoiding unnecessary invasive tests,
boosting physician and/or patient satisfaction, im-
proving quality of life, or beneﬁting other aspects of
health care delivery, cost, or comparable metrics. The
success or failure of a POC diagnostic depends criti-
cally on establishing clearly stated goals and con-
ducting rigorous research to evaluate its ability to
meet pre-speciﬁed objectives. Anticipating potential
risks of POCT has equal importance. For example,
more diagnostic availability could conceivably in-
crease testing volume and cost. More testing may
also triggermore false positive results and lead tomore
invasive downstream testing, which would needlessly
alarm patients and practitioners alike. Research that
addresses such health systems and patient-provider
communication issues associated with POCT could
vitally and meaningfully affect patient care.
ETHICAL AND REGULATORY CONSIDERATIONS.
Although POC testing offers many advantages as a
clinical tool, decentralization of diagnostic testing
may require new regulations to maintain procedural
standardization, adherence to calibration standards,
and maintenance of patient privacy. The FDA, in its
oversight role, has provided related guidance such as
the “regulatory oversight framework for laboratory
developed tests” and the “mobile medical application
policy” (73,74). Practitioners should also be aware
that under current regulatory requirements, POC de-
vices are not necessarily waived under CLIA (Clinical
Laboratory Improvement Amendments) simply
because of use at the point of care. The use of POC
devices for clinical research requires development of
a policy regarding sharing of results with participants.
Protecting the health information of patients re-
mains fundamental to clinical care by ethics and
statute. The design, ownership, and operation of new
POC devices requires cooperation by multiple part-
ners to capitalize on the data collected without
compromising patient privacy. These concerns mirror
those currently encountered with widespread adop-
tion of electronic health records. Yet, the mobile
nature of POC devices decentralizes privacy preser-
vation and entrusts sensitive patient data to a broad
range of individuals spanning health care specialists
to POC data management service providers. The
active research of the HHS suggests the need to
update provisions of the Health Insurance Port-
ability and Accountability Act of 1996, now inﬂuenced
by challenges related to the rapid developments
of health information technology, includingimplementation of electronic medical records and
mobile technologies for health care (75).
POCT AS A CLINICAL RESEARCH TOOL
POCT have considerable potential to enhance clinical
research. Biomarkers can contribute to clinical trials
by complementing clinical endpoints with interim
measurements that can deepen understanding of in-
terventions. In this context, POC diagnostics offer
powerful opportunities to enrich biomarker collection
during the conduct of well-controlled clinical trials
with carefully adjudicated endpoints. Ambulatory
monitoring devices such as mobile device applica-
tions, wearable monitors, and home-based sensors
remain some of the most attractive POCT categories
as aids to clinical investigation. Unlocking the vast
assortment of uncaptured ambulatory data presents
an opportunity for POC devices to enrich substan-
tially clinical trial data collection. Similarly, bioﬂuid
sampling during clinical trials remains a valuable
resource when paired with carefully curated patient
populations meeting well-deﬁned entry criteria that
can correlate with carefully adjudicated endpoints.
Yet, limits pertain to the number of bioﬂuid bio-
markers that conventional assays can measure. POC
technologies that seek to multiplex biomarker mea-
surements have a tremendous potential to maximize
the information yield from these scarce samples and
facilitate biomarker discovery, biomarker validation,
and mechanistic insight.
Additional beneﬁts of POCT in clinical research
include enabling novel patient recruitment pathways
by facilitating screening for eligibility criteria without
requiring centralized testing or return visits. POCTs
also offer ﬂexible pathways for baseline and follow-
up data collection, providing opportunities to
improve clinical trial quality control through longi-
tudinal and site-speciﬁc monitoring of study protocol
compliance. POC diagnostics could expand opportu-
nities for clinical trial participation beyond heavily
populated urban areas, where trial coordination is
typically centered. Doing so will reduce the inherent
selection bias associated with existing geographic
constraints and make trial results more relevant to a
broader population. The National Institutes of Health
has initiated funding for several clinical trials to test
such technologies; continued development of this
approach will represent an important advance in CV
clinical research (see Table 1 for examples).
Clinical research in the developing world often
focuses on communicable diseases; however, CV
disease remains the leading cause of death worldwide
and does not spare low- and middle-income
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83countries (6). In resource-limited environments
where geographic and ﬁnancial constraints limit the
availability of centralized laboratories, catheteriza-
tion facilities, and specialty CV care, the relationship
between diagnostic testing and CV disease manage-
ment differs dramatically from heavily populated
urban centers. Thus, these settings will require
dedicated clinical research to understand how POCT
can answer the special needs of these environments.
In principle, POCTs that minimize instrumentation
and infrastructure demands offer particular promise
in these settings. Several platforms in development
that use “lab-on-a-chip” technologies featuring inte-
grated sample acquisition, processing, and measure-
ment may address these needs. Those that interface
with smart phone technologies are particularly
attractive given the broad availability of cell phones
in rural areas and the developing world (50).
ROADMAP FOR CV CLINICAL RESEARCH
POCT DEVICE DEVELOPMENT
POCTs have tremendous potential to advance CV
care. Realizing this potential will require a funding
environment that incentivizes engineering solutions
beyond mere proof of concept demonstrations and
cultivates them throughout the full technology
development life cycle. Through close collaboration,
engineers and health care providers must work
together to ensure that innovative POC devices have a
path for clinical testing, regularly undergo quantita-
tive comparison to modern standards of care, and
require careful monitoring to achieve POC goals
without making excessive performance compromises.
The NHLBI occupies an ideal position to incentivize
formation of multidisciplinary teams comprised of
health care providers, biomarker scientists, technol-
ogists, and clinical trialists to collaborate longitudi-
nally throughout the development process. To guide
the activities of these CV POCT teams, the NHLBI WG
proposes the following 5-stage CV POCT Devel-
opment Roadmap. This approach aims to capitalize
on advances in biomarker science and emerging
sensor technologies to create clinically relevant POC
devices with a deﬁned path for rigorous clinical
testing and validation.
1. Needs identiﬁcation. Stage 1 goals include the
identiﬁcation of speciﬁc aspects of clinical care
that have potential for substantial improvement by
POCT “clinical needs” and the articulation of (well-
posed) clinical problems that carefully describe the
process of testing a speciﬁc POCT solution (which
patient population, what clinical setting, the
methods behind the quantitative measurement ofbeneﬁts and risks, and the standard[s] of care that
will serve as comparison).
2. Biomarker selection and device design speciﬁcation.
Stage 2 will bring biomarker scientists and tech-
nologists together to take the “well-posed clinical
problem” from stage 1 and use it to both select a
relevant set of new and/or old biomarker(s) and
deﬁne design criteria for a corresponding POC
measurement device. Deﬁning the clinical objec-
tives early increases the likelihood of success once
the technology exists.
3. Device development. Stage 3 will focus on devel-
opment of component technologies and system
integration, leading to a functional POC measure-
ment device. Guided by the speciﬁcations deﬁned
in stage 2, an iterative process of design, fabrica-
tion, and testing of key technologies and individ-
ual components will be undertaken. This will
culminate with a system integration process that
will require additional engineering and perfor-
mance characterization using simpliﬁed models of
the relevant human biomarkers.
4. Pilot testing. Stage 4 will use the POC solution
developed in stage 3 to perform pilot testing on
clinical samples or small-scale patient populations.
This effort will help identify obstacles associated
with real-world biosamples, identify normal
ranges and intervention thresholds, highlight data
management issues, reveal unanticipated human
factors, and provide initial data on device usability
in a real-world clinical setting. An iterative process
of device reﬁnement and repeat pilot testing will
prepare the technology for rigorous clinical testing
in stage 5.
5. Prospective clinical testing. Stage 5 will test and
validate the technology in “real-world” health care
settings. Assessment of device efﬁcacy as well as
liabilities and risks remains the overall goal.
Because design tradeoffs are device- and
application-speciﬁc, the criteria for success will
need to be deﬁned on a case-by-case basis (deﬁned
during stages 1 and 2). Acceptance of methodolo-
gies and validation studies for all new diagnostics
including POC should require transparency and
peer-reviewed publication.RECOMMENDATIONS FOR
NHLBI CV POCT PRIORITIES
 Support Stage 1 activities with the engagement of
the broad CV and bioengineering communities in
pre-competitive CV POCT needs-assessment ac-
tivities. This action would ideally extend beyond a
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84single meeting to include the creation of a forum
for an ongoing electronic and living discussion
that encourages broad participation from diverse
backgrounds and spans multiple training levels. A
multidisciplinary team of experts can consolidate,
curate, and reﬁne contributions to create a
focused list of Cardiovascular POCT Grand Chal-
lenges that correspond to the most promising
“well-posed clinical problems.” The most attractive
Challenges will ideally extend beyond modest re-
ductions in assay sample volume or increased
portability of existing biomarker measurements,
and instead pursue ambitious goals that ensure
that novel CV POCT can improve dramatically
CV care. Challenges that offer an opportunity for
the CV POCT community to coalesce around a
small number of high-impact problems are most
likely to inspire development of high impact
technologies.
 Support stage 2 activities with the funding of
biomarker science (basic discovery and validation
of novel CV biomarkers) and novel sensing tech-
nologies (methods for detecting and quantifying a
variety of biomarkers from diverse patient-derived
samples). This fundamental work will cut across
individual clinical POC devices and provide a sci-
entiﬁc and technological basis for integrated POC
solutions.
 Support stage 3 activities with the funding of
speciﬁc implementations of biomarker-sensing so-
lutions that range from individual sensing compo-
nents to complex, fully integrated POC sensing
platforms that perform “sample-to-answer” mea-
surements from clinically relevant specimens.
 Support stage 4 activities by enabling pilot testing
of integrated “sample-to-result” technologies
developed in stage 3 via small-scale, proof-of-
concept studies in preparation for larger-scale
prospective POC testing in stage 5. Support could
include facilitating access to annotated clinical
specimens. Such pilot testing can also help deter-
mine reference values for POC tests in relevant
populations, encourage harmonized data stan-
dards and reporting of POC tests, and determine
the data and technical integration needs at
different levels (e.g., technical, systems, patient
data, and population).
 Support stages 4 and 5 with core data storage, data
processing, privacy, and analytics that will permitthe transmittance of POCT results to and from pa-
tients and providers to realize their power without
compromising patient privacy.
 Integrate stage 4 and 5 POCT activities with
ongoing or planned clinical studies funded by the
NHLBI using funding mechanisms such as ancillary
studies or Small Business Innovation Research/
Small Business Technology Transfer grants, and
make existing clinical data and relevant biobanks
accessible to aid validation of POC technologies
against established centralized laboratory
measurements.
 Assess standards for evaluation and clinical use
of POC tests through the establishment of
application-speciﬁc standards of quality, efﬁ-
ciency, affordability, accessibility, and safety of
devices and data (in coordination with other
appropriate agencies.)
 Fund career development activities, program for-
mation, and industry surrounding novel biomarker
science and POC technology development that
provides the foundation for new POCT opportu-
nities on the basis of previously unrecognized or
unmeasurable biomarkers.
POCT possess the potential to transform medical
research and patient care. Implementation of a
research and development program as proposed in
the roadmap and recommendations that emerged
from this WG can accelerate the realization of this
promise.
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